Kamada (KMDA) is a biopharmaceutical with a favorable Growth Score and top Zacks Rank. The company's projected earnings growth of 50.7% outpaces the industry average of 18.4%. Additionally, Kamada has an impressive asset utilization ratio of 0.46, indicating efficient use of assets to generate sales, and expected sales growth of 12.4% this year.
Kamada (KMDA) closed the last trading session at $7.02, gaining 2.5% over the past four weeks. Wall Street analysts are optimistic about the biopharmaceutical company's prospects, with a mean price target of $14.75, indicating an 110.1% upside potential [1].
The average price target, ranging from $11.00 to $20.00, has a standard deviation of $3.86, suggesting a high degree of agreement among analysts about the direction and magnitude of KMDA's price movement [1]. While the consensus price target is widely sought after by investors, it should be treated with skepticism due to the potential biases and business incentives of analysts [1].
Kamada's impressive average price target is not the only indicator of potential upside. The company's projected earnings growth of 50.7% outpaces the industry average of 18.4%, and it has an impressive asset utilization ratio of 0.46, indicating efficient use of assets to generate sales [3]. Additionally, expected sales growth of 12.4% this year further supports a positive outlook [3].
The Zacks Consensus Estimate for the current year has increased 14.1% over the past month, with two estimates going higher compared to no negative revision. Furthermore, KMDA currently has a Zacks Rank #2 (Buy), placing it in the top 20% of more than 4,000 stocks ranked based on earnings estimates [1].
While the consensus price target may not be a reliable indicator of how much KMDA could gain, the direction of price movement it implies does appear to be a good guide. Investors should consider KMDA's strong fundamentals and positive earnings revisions when evaluating the stock's potential upside.
References:
[1] https://www.nasdaq.com/articles/wall-street-analysts-see-11011-upside-kamada-kmda-can-stock-really-move-high
[2] https://finance.yahoo.com/news/wall-street-analysts-see-110-135502758.html
[3] https://seekingalpha.com/article/4817227-kamada-earnings-expansion-cycle-with-embedded-margin-of-safety
Comments
No comments yet